ePT--the Electronic Newsletter of Pharmaceutical Technology, Dec 16, 2010 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Dec 16, 2010
News
J&J Voluntarily Recalls Rolaids Products
By Patricia Van Arnum
McNeil Consumer Healthcare, a division of McNEIL-PPC, part of Johnson & Johnson (J&J, New Brunswick, NJ) issued a voluntary recall on Dec. 9, 2010, for Rolaid products in the United States and Canada due to reports of possible product contamination.
A Bad Year for Pharmaceutical R&D
By Stephanie Sutton
Figures released by the European Medicines Agency regarding the evaluation of marketing authorization (MA) applications show a significant decline in the number of approved products for 2010.
Abbott, B. Braun, and Roxane Pay $421.2 Million to Settle False-Claims Allegations
By Erik Greb
Abbott Laboratories (Abbott Park, IL), B. Braun Medical (Bethlehem, PA), and Roxane Laboratories, a subsidiary of Boehringer Ingelheim (Ingelheim am Rhein, Germany), agreed to pay the United States $421 million to settle False Claims Act allegations.
Pfizer's Thelin Withdrawn Due to Fatalities
By Stephanie Sutton
Following two cases of fatal liver injury, Pfizer has voluntarily withdrawn Thelin from the worldwide market and discontinued all ongoing trials.
Week of Dec. 13, 2010: Company and People Notes: Thermo Fisher to Acquire Dionex; Former SOCMA CEO Joe Acker Dies; and More.
Thermo Fisher to Acquire Dionex; Former SOCMA CEO Joe Acker Dies; and More.
Regulatory Roundup: FDA Issues Final Guidance on How to Comment on Advisory Committee Meetings
FDA Issues Final Guidance on How to Comment on Advisory Committee Meetings

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
Click here